Melanoma Clinical Trials

Showing 1-2 of 2 items
  • RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC and Melanoma)
  • This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of RTA 408 in patients with advanced solid tumors that are refractory after standard of care therapy for the disease. The results of this study will help provide clinical information for the design and conduct of further clinical studies with RTA 408 in cancer patients.
  • Diagnoses: Melanoma
  • Status: Recruiting
Showing 1-2 of 2 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms